30808 Federal Register / Vol. 72, No. 106 / Monday, June 4, 2007 / Notices 

research to further develop, evaluate, or 

commercialize this technology. Please 

contact John D. Hewes, Ph.D., at 301/ 

435–3121 or hewesj@mail.nih.gov for 

more information. 

Conjugates of Ligand, Linker, and 

Cytotoxic Agent and Related 

Compositions and Methods of Use 

Description of Technology: Systemic 

toxicity of drugs is one of the most 

serious problems in cancer 

chemotherapy and frequently is dose 

limiting. Specific delivery of cytotoxic 

drugs to cancer cells remains among the 

most intractable problems of cancer 

therapy. Targeted delivery of antiproliferation drugs through the cell 

surface receptors that are over expressed 

on cancer cells can reduce systemic 

toxicity and increase effectiveness of a 

treatment. 

The present invention describes 

cytotoxic compounds with an 

intracellular target that can selectively 

enter tumor cells through specific 

receptors on the cell surface. The 

invention also describes a conjugate 

comprising a cytotoxic agent, a linker 

arm and a ligand capable of delivering 

a cytotoxic agent in a cell specific 

manner. Such conjugates of a cytotoxic 

agent and a ligand (delivery moiety) 

have increased selectivity for tumor 

cells. The toxic moiety and the ligand 

are joined by a linker arm that is stable 

in circulation, but is easily cleaved in 

lysosomes upon internalization of the 

conjugate. A panel of compounds 

comprised of a variety of cytotoxic 

warheads, against various intracellular 

targets linked to an assortment of 

ligands, has been developed and tested 

in a model system. Ligand moieties of 

these conjugates are capable of specific 

delivery of cytotoxic agents to receptors 

that are frequently over expressed in 

gastric, colon, lung, breast, ovarian and 

pancreatic tumors. These compounds 

have the potential to be highly effective 

anti-tumor agents with considerably 

little negative effect. This disclosed 

technology could provide new and 

exciting methodologies to treat cancer. 

Inventors: Nadya I. Tarasova et al. 

(NCI) 

Patent Status: U.S. Patent Application 

No. 10/505,239 filed 19 Aug 2004, 

claiming priority to 27 Feb 2002 (HHS 

Reference No. E–057–2002/2-US–02). 

Licensing Contact: Adaku 

Nwachukwu, J.D.; 301/435–5560; 

madua@mail.nih.gov. 

DLC–1 Gene Deleted in Cancers 

Description of Technology: 

Chromosomal regions that are 

frequently deleted in cancer cells are 

thought to be the loci of tumor 

suppressor genes, which restrict cell 

proliferation. Recurrent deletions on the 

short arm of human chromosome 8 in 

liver, breast, lung and prostate cancers 

have raised the possibility of the 

presence of tumor suppressor genes in 

this location. 

The inventors have discovered the 

deletion of human DLC–1 gene in 

hepatocellular cancer (HCC) cells. They 

have performed in vitro experiments 

demonstrating the deletion in over 40% 

of human primary HCC and in 90% of 

HCC cell lines. The DLC–1 gene is 

located on human chromosome 8p21.3–

22, a region frequently deleted in many 

types of human cancer. DLC–1 mRNA is 

expressed in all normal tissues tested, 

but it has either no or low expression in 

a high percentage of several types of 

human cancer, such as liver, breast, 

lung, and prostate cancers. Through in 

vitro and in vivo tumor suppression 

experiments, the inventors further 

demonstrated that DLC–1 acts as a new 

tumor suppressor gene for different 

types of human cancer. 

Applications: Method to diagnose 

HCC; Method to treat HCC patients with 

DLC–1 compositions; Transgenic model 

to study HCC and other types of human 

cancer; DLC–1 compositions. 

Market: Primary liver cancer accounts 

for about 2% of cancers in the U.S., but 

up to half of all cancers in some 

undeveloped countries; 251,000 new 

cases are reported annually; postoperative five year survival rate of HCC 

patients is 30–40%. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Bao-Zhu Yuan, Snorri S. 

Thorgeirsson, Nicholas Popescu (NCI). 

Publications: 1. BZ Yuan et al. DLC–

1 operates as a tumor suppressor gene 

in human non-small cell lung 

carcinomas. Oncogene. 2004 Feb 

19;23(7):1405–1411. 

2. BZ Yuan et al. DLC–1 gene inhibits 

human breast cancer cell growth and in 

vitro tumorigenicity. Oncogene. 2003 

Jan 23;22(3):445–450. 

3. BZ Yuan et al. Promoter 

hypermethylation of DLC–1, a candidate 

tumor suppressor gene, in several 

common human cancers. Cancer Genet 

Cytogenet. 2003 Jan 15;140(2):113–117. 

4. BZ Yuan et al. Cloning, 

characterization, and chromosomal 

localization of a gene frequently deleted 

in human liver cancer (DLC–1) 

homologous to rat RhoGAP. Cancer Res. 

1998 May15;58(10):2196–2199. 

Patent Status: U.S. Patent No. 

6,897,018 issued 24 May 2005 (HHS 

Reference No. E–042–1998/0–US–03). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov 

Collaborative Research Opportunity: 

The National Cancer Institute, 

Laboratory of Experimental 

Carcinogenesis, is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize diagnostics based on 

tumor suppressor genes. Please contact 

John D. Hewes, Ph.D., at 301/435–3121 

or hewesj@mail.nih.gov for more 

information. 

Dated: May 23, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–10712 Filed 6–1–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Board of Scientific Counselors for 

Clinical Sciences and Epidemiology 

National Cancer Institute. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Cancer Institute, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors for Clinical Sciences and 

Epidemiology National Cancer Institute. 

Date: July 10, 2007. 

Time: 9 a.m. to 3:30 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institutes of Health, 

National Cancer Institute, 9000 Rockville 

Pike, Building 31, Conference room 10, 

Bethesda, MD 20892. 

Contact Person: Brian E. Wojcik, PhD, 

Senior Review Administrator, Institute 

Review Office, Office of the Director, 

National Cancer Institute, 6116 Executive 

Boulevard, Room 2114, Bethesda, MD 20892, 

(301) 496–7628, wojcikb@mail.nih.gov. 


rwilkins on PROD1PC63 with NOTICES
Federal Register / Vol. 72, No. 106 / Monday, June 4, 2007 / Notices 30809 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/bsc.htm, where 

an agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: May 25, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2752 Filed 6–1–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Board of Scientific Counselors for Basic 

Sciences National Cancer Institute. The 

meeting will be closed to the public as 

indicated below in accordance with the 

provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Cancer Institute, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors for Basic Sciences National 

Cancer Institute. 

Date: July 9, 2007. 

Time: 9 a.m. to 3 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institutes of Health, 

National Cancer Institute, 9000 Rockville 

Pike, Building 31, Conference Room 6, 

Bethesda, MD 20892. 

Contact Person: Florence E. Farber, PhD, 

Executive Secretary, Office of the Director, 

National Cancer Institute, National Institutes 

of Health, 6116 Executive Boulevard, Room 

2115, Bethesda, MD 20892, 301–496–7628, 

ff6p@nih.gov. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: May 25, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2753 Filed 6–1–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the President’s Cancer 

Panel, May 24, 2007, 12:30 p.m. to May 

24, 2007, 2:30 p.m. National Institutes of 

Health, 6116 Executive Boulevard, 

Rockville, MD 20852 which was 

published in the Federal Register on 

May 4, 2007, 72 FR 25322. 

This meeting has been rescheduled to 

occur on June 14, 2007 from 9 a.m. to 

10 a.m. The meeting is closed to the 

public. 

Dated: May 25, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2756 Filed 6–1–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meetings 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of meetings of the 

National Cancer Institute Clinical Trials 

Advisory Committee. 

The meetings will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Cancer 

Institute Clinical Trials Advisory Committee, 

Coordination Subcommittee. 

Date: July 10, 2007. 

Time: 7 p.m. to 9 p.m. 

Agenda: Provide advice to the Director, 

NCI on how to foster collabration among the 

various components of the NCI-support 

clinical trials infrastructure. 

Place: Pooks Hill Bethesda Marriott, 5151 

Pooks Hill Road, Bethesda, MD 20814. 

Contact Person: Sheila A. Prindiville, MD, 

Director, Coordinating Center for Clinical 

Trials, Office of the Director, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Blvd., Suite 507, Bethesda, MD 

20892, 301–451–5048, 

prindivs@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Clinical Trials Advisory Committee; 

CTAC. 

Date: July 11, 2007. 

Time: 8:30 a.m. to 4 p.m. 

Agenda: Update on the Clinical Trials 

Working Group Implementation. 

Place: National Institutes of Health, 

Building 31, 6th Floor, C–Wing, 31 Center 

Drive, Conference Room 10, Bethesda, MD 

20892. 

Contact Person: Sheila A. Prindiville, MD, 

Director, Coordinating Center for Clinical 

Trials, Office of the Director, National Cancer 

Institute, National Institutes of Health, 6116 

Executive Blvd., Suite 507, Bethesda, MD 

20892, 301–451–5048, 

prindivs@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 


rwilkins on PROD1PC63 with NOTICES